Diclofenac sodium long-acting 100 mg tablets: Discontinuation

Discontinuation Active

We are discontinuing the supply of diclofenac sodium long-acting 100 mg tablets from 1 May 2022. All other current strengths of diclofenac sodium remain available.

Why are we doing this?

Diclofenac sodium long-acting 100 mg tablets was supplied by Apotex. Apotex is leaving the New Zealand market. We have been looking for new suppliers for all the medicines they currently supply.

Due to globally declining volumes of this presentation of diclofenac sodium, we have been unable to find an alternative supplier for this product. 

Key dates

October 2021: Stock exhausted

We anticipate that stocks of diclofenac sodium long-acting 100 mg tablets will be exhausted by October 2021.  

1 May 2022: tablets delisted

The May 2022 delisting date allows for dispensing of residual stock within the supply chain. 

Alternative product 

There are a range of other non-steroidal anti-inflammatory drugs (NSAIDs) funded and available, including other presentations of diclofenac sodium. We have received clinical advice that these would be suitable alternatives for people to be transitioned to. 

NSAIDs | NZ Formulary(external link)

NSAIDs | Pharmaceutical Schedule(external link)

Who to contact 

If you are taking diclofenac sodium long-acting 100 mg tablets, talk to your pharmacist or the person who prescribed it to you.  They are in the best place to advise on your clinical circumstances.

If you have funding questions about diclofenac sodium long-acting 100 mg tablets, email enquiry@pharmac.govt.nz

Pharmac's response to Apotex's departure